ReShape Lifesciences Inc. (RSLS) reported company developments tied to weight loss and metabolic health products for obesity and metabolic disease. Its product references include the FDA-approved Lap-Band System for minimally invasive obesity treatment, the investigational Diabetes Bloc-Stim Neuromodulation system using vagus nerve block and stimulation technology for type 2 diabetes and metabolic disorders, and Obalon balloon technology for a swallowable intragastric balloon approach.
Recurring RSLS news categories include clinical and regulatory disclosures, intellectual-property updates for intragastric balloon systems, surgeon education around Lap-Band, shareholder voting matters, governance items, material agreements, security-structure disclosures, and capital-structure actions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.